Abstract 1164P
Background
The standard approach for managing locally advanced rectal cancer includes preoperative neoadjuvant chemoradiotherapy followed by curative surgery, a regimen acknowledged for substantially enhancing local control rates. Nevertheless, the benefits of perioperative radiotherapy in treating rectal neuroendocrine carcinoma merit further investigation. This study explores the impact of preoperative neoadjuvant radiotherapy on the feasibility of sphincter-preserving surgery and on the overall survival rates in patients with locally advanced rectal neuroendocrine carcinoma.
Methods
Data from patients diagnosed with locally advanced (T3/T4 or N+) neuroendocrine carcinoma who underwent curative surgery from 2004 to 2019 were collected using the SEER database. We assessed clinical characteristics, treatment information, and overall survival rates. Statistical comparisons of categorical variables were performed using the Chi-square test or Fisher's exact test. Survival outcomes were analyzed using the Kaplan-Meier method.
Results
Of the 44 patients identified, 14 underwent preoperative neoadjuvant radiotherapy. Patients with a T-stage above T3 (42.9% vs. 12.5%, P = 0.049) and those without lymph node metastasis (87.5% vs. 19.4%, P < 0.001) were more likely to receive perioperative radiotherapy. The probability of performing sphincter-preserving surgery was notably lower in patients treated with neoadjuvant radiotherapy (57.1% vs. 93.3%, P = 0.008). Additionally, survival analysis indicated no significant relationship between neoadjuvant radiotherapy and overall survival (HR 1.298,95% CI:0.519-3. 244, P =0. 577).
Conclusions
Neoadjuvant radiotherapy prior to surgery did not improve the likelihood of performing sphincter-preserving procedures in patients with locally advanced rectal neuroendocrine carcinoma, nor did it significantly impact overall survival. Further research involving larger sample sizes is required to confirm these findings.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work, the author(s) used ChatGPT for editorial assistance in order to optimize content expression. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
W. Xu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
498P - Report of 9 cases of embryonal tumours of the central nervous system with multilayered rosettes (ETMR)
Presenter: Ruyu Ai
Session: Poster session 17
Resources:
Abstract
499TiP - A phase II study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Presenter: Brian Stockdale
Session: Poster session 17
500TiP - Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Presenter: Michael Weller
Session: Poster session 17
501TiP - Clinical performance evaluation of a brain cancer liquid biopsy
Presenter: James Cameron
Session: Poster session 17
692P - Role of adjunctive surgery after platinum-based chemotherapy in management patients with adrenocortical carcinoma: Observation study
Presenter: Yaroslav Zhulikov
Session: Poster session 17
693P - Causes of death in patients with malignant adrenal tumors: A population-based analysis
Presenter: Shangqing Ren
Session: Poster session 17
946P - Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study
Presenter: Jung Sun Kim
Session: Poster session 17
948P - Drug type and duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors (PREVENT): An update analysis of a prospective, multicentric cohort study
Presenter: Jia-Yong Su
Session: Poster session 17
Resources:
Abstract
949P - Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
Presenter: Xianhai Mao
Session: Poster session 17
950P - Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Presenter: Masatoshi Kudo
Session: Poster session 17